GLICLAZIDE EVOLUGEN 60 mg, scored tablet with modified release 30 tablets
Active ingredients: Gliclazide
Commercialized according to BDPMDispensing in France: Prescription only
Scored tablet with modified release30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- GLICLAZIDE EVOLUGEN 60 mg, comprimé sécable à libération modifiée
- Pharmaceutical form
- comprimé sécable à libération modifiée
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s)
- Marketing authorisation holder
- EVOLUPHARM
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 10 Aug 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61651374CIP73006945CIP133400930069455Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| GLICLAZIDEcomprimé | 60 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.